Patient Essays Expose Insurer Step Therapy and Claim Denials in Cancer Care as Safe Step Act Push Advances
核心洞察
Two first-person patient accounts describe insurer and pharmacy benefit manager denials that delayed or overrode oncologist-recommended cancer treatment, including a breast cancer (搜索) patient denied milder chemotherapy.
A chronic myelogenous leukemia (搜索) patient says he was required to try and fail on insurer-preferred drugs before coverage, a practice known as step therapy that he calls potentially deadly.
ProPublica data cited in one account show more than 49 million US claims were denied in 2021, yet only 0.2% were appealed as automated systems increasingly assess claims.
Two first-person accounts published by patients with cancer describe how insurer and pharmacy benefit manager coverage decisions overrode or delayed treatments their oncologists had recommended, adding detail to an ongoing policy fight over step therapy and claim denials in the United States.
In an essay published by Vanity Fair, a writer diagnosed with breast cancer (搜索) at age 36 recounts that in the summer of 2024 her oncologist called to say her insurance company would not pay for a milder chemotherapy regimen her physician considered appropriate alongside a year of targeted therapy. The insurer would cover only the standard of care, Taxol — a chemotherapy she had already received, with side effects she described as including memory loss, neuropathy, total alopecia, nausea, vomiting, and dangerously elevated liver enzymes. Her oncologist had appealed the denial multiple times without success, and the patient said paying for the milder chemotherapy herself would have forfeited coverage of the targeted therapy, which she described as $18,000 per shot across 18 cycles.
The essay states that every week of delay carried an increased risk of recurrence and that nearly a month had already been lost to denials. After the patient emailed the insurer's chief executive, the company's chief scientific officer replied that the request would be approved the next day per the oncologist's request, and executives subsequently authorized the milder chemotherapy and apologized. She reported going into remission that fall.
The account also cites ProPublica figures that more than 49 million claims were denied in the United States in 2021, with only 0.2% appealed, as insurers increasingly rely on automated systems to assess claims. The writer argues that further automation could remove human intermediaries from coverage decisions entirely, and references an estimated 68,000 unnecessary deaths a year that she attributes to the absence of Medicare for All. She also describes the December shooting of the chief executive of UnitedHealthcare (搜索), an insurer she says was not her own, and the public reaction to it, while stating she does not endorse the action.
A separate opinion piece in The Philadelphia Inquirer describes a patient living with cancer for nearly two decades who was diagnosed with chronic myelogenous leukemia (搜索) (CML), a cancer that begins in the bone marrow, in 2010 after presenting with trouble sleeping, frequent heartburn, and a persistent cough. Despite having insurance coverage, he writes, he learned the insurer had a treatment plan of its own that differed from his oncologist's prescription: before granting coverage, the insurer required him to try and fail on medications it preferred — a practice known as step therapy.
"For cancer patients, it can be deadly," the patient writes, adding that "failure is not really a word you want to be part of the discussion when it comes to cancer." He identifies pharmacy benefit managers including OptumRx (搜索), Express Scripts (搜索), and CVS Caremark (搜索) as companies that profit from controlling which drugs are covered and in what order. He notes that for patients with other blood cancers such as chronic lymphocytic leukemia (搜索), the most common adult leukemia, delays and forced substitutions can allow the disease to evolve in ways that close the window on the best available treatment entirely.
The CML patient writes that had he been diagnosed 10 years earlier, treatment would have included chemotherapy or a bone-marrow transplant, whereas the most effective option for his leukemia today is daily oral anti-cancer therapy, with no comparable IV medications, allowing him to continue working and to run again. He says his oncology team enrolled him in a drug company program that supplies his medication directly at low cost after his insurer tried to force an alternative treatment plan, and that without that option he could face delays and denials.
On policy, the Inquirer piece points to a letter from House Oversight Committee (搜索) Chair James Comer to CMS administrator Mehmet Oz calling on the Centers for Medicare and Medicaid Services (搜索) to do more to protect Medicare Part D patients from insurer- and pharmacy benefit manager-imposed step therapy. It notes that Part D plans are already bound by national cancer treatment guidelines stating that not all cancer drugs are interchangeable, yet insurers and their pharmacy benefit managers routinely substitute treatments for financial rather than medical reasons. The author credits Comer with a critical role in crafting pharmacy benefit manager reforms and urges Congress to pass the Safe Step Act, which would ensure patients can receive timely exceptions when step therapy is medically inappropriate, and asks the Pennsylvania federal delegation to support it.